Table 2. Additional clinical information of the patients with previously normal testosterone who subsequently developed low testosterone after treatment with immunotherapy.
| Clinical information of patients with normal T who developed low T after immunotherapy | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Pt | Age at diagnosis | Immunotherapy Agent(s) | Baseline T | Lowest T value | Resolution of low T | Comorbidities | Radiation | Clinical trial | Endocrine dysfunction during tx |
| 1 | 50 | Ipilimumab, Pembrolizumab | Normal (314) | 55 | No | Heart disease | Local | - | - |
| 2 | 72 | Ipilimumab | Normal (498) | 78 | No | - | - | - | - |
| 3 | 66 | Pembrolizumab | Normal (319) | 144 | No | Heart disease | Brain | - | Pituitary, adrenal |
| 4 | 61 | Ipilimumab, Pembrolizumab | Normal (338) | 69 | No | Obese, heart disease, diabetes, hypothyroid | Brain | Yes | - |
| 5 | 82 | Pembrolizumab | Normal (399) | 181 | No | Heart disease, diabetes | - | - | - |
| 6 | 59 | Ipilimumab, Pembrolizumab | Normal (419) | < 5 | No | Obesity, heart disease | Local | - | Hypophysitis |
| 7 | 35 | Ipilimumab, Pembrolizumab | Normal (524) | 170 | Yes | Obesity | Brain | Yes | Pituitary, thyroid |
| 8 | 85 | Pembrolizumab | Normal (351) | 206 | Yes | Obesity, heart disease, previous prostate cancer | - | - | Pituitary, adrenal |
| 9 | 46 | Pembrolizumab | Normal (369) | 22 | Yes | - | - | - | Adrenal |
| 10 | 52 | Pembrolizumab | Normal (456) | 133 | Yes | Obesity, heart disease, OSA, previous melanoma | Local | - | Pituitary, adrenal, and thyroid |
| Avg: | 60.8 | 398.7 | 105.8 | ||||||
While these patients had diverse treatment courses, most of these patients had multiple comorbidities prior to their development of low testosterone.